Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atomic force microscopy identifies filamentous structures comprising mitotic chromosomes.

Biomedical research (Tokyo, Japan)·2026
Same author

The Role of Glycans and Glycosyltransferases Involved in N-glycan Branching in Cancer, COPD, Alzheimer's Disease, and Redox Regulation.

Journal of visualized experiments : JoVE·2026
Same author

Pentosidine accumulation induced by Akr1a deficiency drives aggression and hyperactivity.

Neuroscience letters·2026
Same author

Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity.

The EMBO journal·2025
Same author

Progressive chromosome shape changes during cell divisions.

EMBO reports·2025
Same author

Roles of Glyco-Redox in Epithelial Mesenchymal Transition and Mesenchymal Epithelial Transition, Cancer, and Various Diseases.

Antioxidants & redox signaling·2024
Same journal

Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.

Cancer science·2026
Same journal

Splicing Factor Mutations in Clonal Hematopoiesis and Progression to Myeloid Neoplasms.

Cancer science·2026
Same journal

Genetic Evolution in BRCA1-Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis.

Cancer science·2026
Same journal

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response.

Cancer science·2026
Same journal

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4.

Cancer science·2026
Same journal

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2.

Cancer science·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development.

Nana Kamakura1, Minji Jo1, Motoko Takahashi1

  • 1Division of Experimental Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Cancer Science
|June 1, 2026
PubMed
Summary
This summary is machine-generated.

Cancer cells exploit cell cycle vulnerabilities for growth. Targeting these weaknesses, like cyclin-dependent kinases (Cdks), offers a promising strategy for selective cancer therapies.

Keywords:
cancercdkcell cyclekinasesynthetic lethalvulnerability

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Experiment Videos

Last Updated: Jun 2, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Area of Science:

  • Cell Biology
  • Cancer Biology
  • Genetics

Background:

  • Cell division ensures genetic material propagation, regulated by cyclin-dependent kinases (Cdks) and cell cycle checkpoints.
  • Cancer involves disrupted cell cycle control, leading to uncontrolled proliferation and genome instability.
  • Compensatory mechanisms in cancer cells create unique vulnerabilities exploitable for therapy.

Purpose of the Study:

  • To review emerging strategies for targeting cancer cell proliferation by exploiting cell cycle dysregulation.
  • To highlight advances in targeting key cell cycle regulators and synthetic lethal interactions.

Main Methods:

  • Review of current literature on cell cycle regulation in cancer.
  • Analysis of therapeutic strategies targeting cyclin-dependent kinases (Cdks), checkpoint kinases, and mitotic kinases.
  • Inclusion of recent findings from CRISPR-genetic screens identifying synthetic lethal genes.

Main Results:

  • Cancer cells exhibit compensatory mechanisms that paradoxically increase sensitivity to specific perturbations.
  • Targeting cell cycle kinases (Cdks, checkpoint, mitotic) presents viable therapeutic avenues.
  • CRISPR screens reveal synthetic lethal interactions offering new targets for cancer treatment.

Conclusions:

  • Exploiting cancer-specific vulnerabilities in cell cycle control is a rational approach for effective and selective cancer therapy.
  • Understanding these dependencies provides a framework for developing novel cancer treatments.